GLMD Stock Shot Up 85% Pre-Market After Rising 27% In 5 Days – What’s The Latest On Its Parkinson’s Disease Therapy?

The biotech firm launched a new formulation of its investigational therapy, which could help treat Parkinson’s disease.
Galmed
Profile Image
Arnab Paul·Stocktwits
Published Apr 09, 2026   |   8:13 AM EDT
Share
·
Add us onAdd us on Google

Shares of Galmed Pharmaceuticals (GLMD) soared more than 85% in pre-market trading on Thursday, after the biotech firm launched a new brain-penetrating formulation of its investigational drug Aramchol.

GLMD stock climbed above $1 in pre-market trading, a level it last reached on December 19. Thursday’s pre-market move comes after an 27% gain over the last five sessions.

The new Aramchol formulation uses lipid nanoparticles delivered via injection and is designed to cross the blood–brain barrier (BBB), a major obstacle that prevents most drugs from reaching the brain. This can be especially useful to treat central nervous system disorders like Parkinson’s disease.

The formulation was developed in collaboration with Barcode Nanotech.

Get updates to this story on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Follow on Google News
Read about our editorial guidelines and ethics policy